Market Place
Sourcing Support
Kiniksa Pharma to Present at 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Kiniksa Pharma to Present at Evercore ISI HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
Kiniksa Pharma to Present at Jefferies London Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
Kiniksa Reports Q3 2024 Financial Results and Portfolio Updates
29 Oct 2024 //
GLOBENEWSWIRE
Kiniksa Partners with Carly for Recurrent Pericarditis Campaign
28 Oct 2024 //
#N/A
Kiniksa Pharmaceuticals To Report Q3 2024 Results On Oct 29
22 Oct 2024 //
GLOBENEWSWIRE
Henrik Lundqvist Teams Up with Kiniksa for Recurrent Pericarditis Campaign
01 Oct 2024 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Kiniksa Reports Q2 2024 Results And Portfolio Execution
23 Jul 2024 //
GLOBENEWSWIRE
Kiniksa To Report Q2 2024 Financial Results On July 23rd
16 Jul 2024 //
GLOBENEWSWIRE
Kiniksa Starts Abiprubart Phase 2b Trial In Sj¶gren Disease
09 Jul 2024 //
GLOBENEWSWIRE
Kiniksa Sponsors AHA’s Addressing Recurrent Pericarditis Initiative
17 Jun 2024 //
GLOBENEWSWIRE
Kiniksa Pharma: Presenting At Goldman Sachs Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
Kiniksa Pharma at BofA Securities Healthcare Conference 2024
06 May 2024 //
GLOBENEWSWIRE
Kiniksa Reports Q1 2024 Financials and Portfolio Execution
23 Apr 2024 //
GLOBENEWSWIRE
Kiniksa to Report Q1 2024 Financials on April 23, 2024
16 Apr 2024 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
02 Apr 2024 //
GLOBENEWSWIRE
Kiniksa Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Provides Corporate Update
04 Jan 2024 //
GLOBENEWSWIRE
Kiniksa Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Kiniksa Reports Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Kiniksa to Report Third Quarter 2023 Financial Results on October 31, 2023
24 Oct 2023 //
GLOBENEWSWIRE
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday
25 Jul 2023 //
FOOL
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results
25 Jul 2023 //
GLOBENEWSWIRE
Kiniksa to Report Second Quarter 2023 Financial Results on July 25, 2023
17 Jul 2023 //
GLOBENEWSWIRE
Kiniksa to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Reports 1Q 2023 FYR and Recent Portfolio Execution
02 May 2023 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results
01 May 2023 //
GLOBENEWSWIRE
Kiniksa Reports Fourth Quarter and Full-Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Kiniksa to Report Fourth Quarter and Full-Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
09 Jan 2023 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
Kiniksa Pharma to Present at Bank of America Securities 2022 Biotech SMID
30 Nov 2022 //
GLOBENEWSWIRE
Kiniksa Pharma to Present at Evercore ISI 5th Annual HealthCONx Conference
23 Nov 2022 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Reports 3Q 2022 FYR and Provides Corporate Update
01 Nov 2022 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results
31 Oct 2022 //
GLOBENEWSWIRE
Kiniksa Announces Closing of Global License Agreement Genentech for Vixarelimab
12 Sep 2022 //
GLOBENEWSWIRE
Roche wagers $190M on off-the-shelf CAR-Ts and ex-Biogen asset
03 Aug 2022 //
FIERCEBIOTECH
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Kiniksa Pharma Announces Global License Agreement with Genentech for Vixarelimab
03 Aug 2022 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
Kiniksa Pharma Reports First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
23 Feb 2022 //
ENDPTS
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
22 Feb 2022 //
GLOBENEWSWIRE
Kiniksa to Report Q4 and Full-Year 2021 Financial Results on February 22, 2022
18 Feb 2022 //
GLOBENEWSWIRE
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab
28 Dec 2021 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results
02 Nov 2021 //
PRESS RELEASE
Kiniksa Announces Launch of ARCALYST Named Patient Program
16 Aug 2021 //
GLOBENEWSWIRE
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
02 Aug 2021 //
GLOBENEWSWIRE
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
08 Jun 2021 //
GLOBENEWSWIRE
Kiniksa Announces Issuance of US Patent for Treatment of Recurrent Pericarditis
08 Jun 2021 //
GLOBENEWSWIRE
Kiniksa Reports Q1 2021 Financial Results
04 May 2021 //
GLOBENEWSWIRE
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
04 May 2021 //
GLOBENEWSWIRE
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial
13 Apr 2021 //
GLOBNEWSWIRE
FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis
22 Mar 2021 //
PHARMATIMES
Kiniksa touts 3rd approval for aging Arcalyst — a good haul for just $5M in cash
19 Mar 2021 //
ENDPTS
US clears Kiniksa`s Arcalyst as first therapy for recurrent pericarditis
18 Mar 2021 //
GLOBENEWSWIRE
Kiniksa whiffs on efficacy trying to repurpose an RA program for Covid-19
22 Dec 2020 //
ENDPTS
Kiniksa whiffs on efficacy trying to repurpose an RA program for Covid-19
22 Dec 2020 //
ENDPTS
